Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clovis Pulls Plug On Rociletinib On Expected FDA Rejection

Executive Summary

Clovis Oncology Inc. on May 5 disclosed the FDA notified the company to expect its application for its experimental lung cancer drug rociletinib to be rejected – something that was widely expected on Wall Street after the firm failed in April to convince a federal panel of experts to back the medicine. Clovis, which is cutting its staff by 35% in the wake of the FDA's snub, now turns its attention to its investigational ovarian cancer drug rucaparib.


Related Content

Boehringer Ingelheim Bullish In Oncology Despite Olmutinib U-Turn
FDA’s Advisory Committees Just Can’t Say “No”
Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base
Yuhan, Luoxin Deal Underscores Asian NSCLC Therapy Needs
Tesaro Doubles On Super NOVA Data, Lifts PARP Competitors
Clovis' Rociletinib Blocked By Tagrisso 'Elephant' At ODAC
Searing FDA Review Reveals More Clovis Credibility Slips
Clovis Crumbles On Data Disclosure, Possible FDA Delay
Fast AZ Tagrisso Approval Springboard For Clovis?
Clovis ovarian cancer drug rucaparib dubbed 'breakthrough'


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts